RDR Staff

Insmed Incorporated announced that it has submitted its New Drug Application for amikacin liposome inhalation suspension (ALIS) to the U.S. FDA.

Hartmann Wellhoefer, M.D., head of medical affairs at Shire, recently sat down with Rare Disease Report to discuss the company's recent work for the rare disease community, particularly lysosomal storage diseases.

In an effort to raise awareness about the rare disease community, ORDI is organizing the Race for 7 run.